Novo Nordisk: How a known weight-loss injection becomes the new beacon of hope against liver disease!

Novo Nordisk expands the therapeutic horizon of its blockbuster Semaglutide, presenting data that demonstrate effective combat against the globally widespread liver disease MASH. The progressive public disease affects an estimated 250 million people worldwide, with around 90% of cases remaining undiagnosed in the early stages due to lack of symptoms. For investors, the study results underpin the transformation of the Danish pharmaceutical giant from a pure weight loss story to a broadly positioned market leader in chronic diseases. The...